Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Colon Cancer treatment details. Chemotherapy. Surgery. The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States



Survival: 9.0 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
Surgery
   
Drugs:
Country: United States
   
City/State/Province: Houston, Texas
   
Hospital: The University of Texas, MD Anderson Cancer Center
   
Journal: Link
   
Date: 1/2004

Description:
Patients: This Phase II study involved 15 evaluable patients with metastatic colorectal cancer (adenocarcinoma).

Treatment: The treatment consisted of the chemotherapy drug exatecan mesylate (DX-8951f) after surgery.

Toxicity: The principal toxicity was neutropenia, with grade 3 and 4 toxicities in three and eight patients, respectively. Non-hematologic toxicities included: fatigue (grade 1-3), nausea (grade 1-2), diarrhea (grade 1-2), abdominal pain (grade 1-3), and fever (grade 1-3).

Results: Median survival time was 9.0 months. The authors concluded that DX-8951f at this dose and schedule had no significant activity in this patient population.

Support: One of the study’s authors is associated with Daiichi Pharmaceutical Corp., the company that manufactures exatecan mesylate (DX-8951f).

Correspondence: Melanie Royce, MD

E-mail to a Friend Email Physician More Information